- Codexis has signed an agreement with Axolabs to evaluate its ECO Synthesis Manufacturing Platform for RNA production.
- The collaboration may support future licensing discussions and broader adoption of enzymatic RNA manufacturing.
Codexis, Inc. has entered into an agreement with Axolabs, part of the LGC Group, under which Axolabs will evaluate Codexis’ ECO Synthesis Manufacturing Platform. The platform is designed to support efficient and scalable RNA manufacturing using enzymatic synthesis.
Under the agreement, Axolabs will gain access to the ECO Synthesis platform to assess its suitability for oligonucleotide therapeutics manufacturing. Codexis said the evaluation could pave the way for future licensing discussions and potentially wider adoption of the technology within contract manufacturing settings.
The collaboration brings together Codexis’ enzymatic solutions for therapeutics manufacturing and Axolabs’ capabilities as an oligonucleotide contract research, development and manufacturing organisation (CRDMO). The companies said the partnership is intended to support more efficient manufacturing approaches for oligonucleotide-based medicines.
“Part of our mission is to expand the reach of our ECO Synthesis Manufacturing Platform through collaborations with best-in-class CDMOs.”
Alison Moore, President and Chief Executive Officer of Codexis
The companies stated that the collaboration reflects a shared focus on advancing manufacturing technologies and supporting access to high-quality oligonucleotide therapeutics globally.
